SAN DIEGO (PRWEB) AUGUST 05, 2021
January Therapeutics announced the appointment of Patrick Kearney, PhD, as Head of Early Research and Development. Dr. Kearney will lead key aspects of the Scientific Team for January’s oncology programs including furthering of the Targeted Oncology Programs, Platform Expansion, and other undisclosed targets.
Dr. Kearney is a former Senior Director of Medicinal Chemistry at Exelixis, where he led teams whose kinase-focused efforts resulted in multiple clinical candidates for oncology and inflammation applications. Additionally, while there, he led both technology development, production, and corporate partnership initiatives to build the company’s screening library. Subsequently, Dr. Kearney founded of HD Sciences to develop nanoparticle-based reagents for use in medicinal chemistry. Immediately prior to joining January Therapeutics, he was a Principal Investigator in Chemistry at Deciphera Pharmaceuticals, where led a team to identify novel kinase inhibitors with that company’s core technology platform.
Dr. Kearney received his B.S. from Carnegie Mellon University and a Ph.D. in Chemistry from the California Institute of Technology. He is listed as an inventor on 20 patent applications and as an author on 17 peer-reviewed articles.
“We are very pleased to welcome Dr. Kearney to January.” said Sam Ellis, CEO of January Therapeutics. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to help patients with cancer. His ability to build teams, and bring success will help January Therapeutics grow to the next level.”
SAN DIEGO (PR WEB) MAY 5, 2021
Dr. Grint has served as the Executive Chairman of the Board of Directors of Cardea Bio since April 2020. He also has served as a member of the Board of Directors and as a member of the compensation committee of Amplyx Pharmaceuticals, Inhibikase Therapeutics and Synedgen.
From 2017 to 2019, Dr. Grint served as Chief Executive Officer of AmpliPhi Biosciences and as a member of AmpliPhi Bioscience’s Board of Directors from 2015 to 2019, additionally from 2014 to 2017 Dr. Grint served as Chief Executive Officer of Regulus Therapeutics, Inc., both publicly traded clinical stage biopharmaceutical companies.
Dr. Grint has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. Dr. Grint has also served in senior management roles at Cerexa, Forest Laboratories, Kalypsys, Pfizer, IDEC Pharmaceuticals, and Schering-Plough Corporation. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and holds a B.Sc. from St. Mary’s Hospital College, University of London and an M.B. and B.S. from St. Bartholomew’s Hospital College, University of London.
“We are very pleased to welcome Dr. Grint as a member of the Board of Director’s” said Sam Ellis, CEO of January Therapeutics. “Dr. Grint’s leadership experience as both a Chief Executive Officer and as a director of privately held and public companies along with his significant experience in clinical pharmaceutical development makes him an important addition to our Board of Directors.”
January Therapeutics is a biotechnology company focused on discovering novel therapeutics that leverage the proven clinical benefits of protein-based nanoparticle formulation. Their initial development programs are focused in oncology, specifically related to therapeutics that treat sarcomas, ovarian, lung and other solid tumors.
SAN DIEGO (PRWEB) APRIL 27, 2021
January Therapeutics today announced the appointment of Daniel C. Maneval, PhD, as Chief Scientific Officer. Dr. Maneval will lead key aspects of the Scientific Team for January’s oncology programs including the JNTX-101 program (pro-drug albumin-encapsulated version of gemcitabine for cancer treatment) and JNTX-104 (albumin-encapsulated 8-chloro-adenosine for AML), and other undisclosed targets.
Dr. Maneval is the former Vice President of Research & Nonclinical Development at Halozyme Therapeutics where he led the expansion of Halozyme’s core technology platforms. In that role he was also an integral part of the team working with strategic partners that gained FDA & EMA approval of several products incorporating the Halozyme technology. Prior to Halozyme Dr. Maneval was the Site Head of Schering-Plough’s gene therapy site in San Diego, and he helped lead Herceptin® from a pre-clinical asset through early-phase clinical trials at Genentech.
Dr. Maneval received his B.S. from Boston University in Biomedical Engineering and a Ph.D. in Biomedical Engineering from the University of Southern California. He has authored over 50 publications and is listed as inventor on over 14 patents.
“We are very pleased to welcome Dr. Maneval to January.” said Sam Ellis, CEO of January Therapeutics. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to help patients with cancer. His ability to build teams, and bring success will help January Therapeutics grow to the next level.”
SAN DIEGO (PRWEB) JANUARY 25, 2021
January Therapeutics, an oncology-focused biopharmaceutical research and development company, today announced the appointment of Steven Rosen, MD as Chief Medical Advisor. Dr. Rosen will support key aspects of clinical development for January’s JNTX-101 program (Pro-drug albumin-encapsulated version of Gemcitabine – a backbone for many cancer treatments) and JNTX-104 (Pro-drug albumin-encapsulated version of 8-Chloro-Adenosine – a drug that has been used in patients with AML). Dr. Rosen will also lead January’s patient advocacy program.
Dr. Rosen is the Provost and Chief Scientific Officer of the City of Hope National Medical Center. In that role he leads the Beckman Research Institute and the Irell & Manella Graduate School of Biological Sciences. Dr. Rosen received both his BS and MD from Northwestern University where he also completed his residency. He has authored over 450 publications in the field of Oncology and serves on a number of oncology foundation boards including AACR, ASCO, and the Leukemia & Lymphoma Society.
“We are very pleased to welcome Dr. Steve Rosen to January” said Sam Ellis, CEO of January Therapeutics. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to January.”
SAN DIEGO (PRWEB) JUNE 17, 2020
January Therapeutics, Inc., a biopharmaceutical research and development company, today announced a research collaboration with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.
The collaboration centers around the application of January’s proprietary Chemistry-enabled Albumin Nanoparticle (CAN) platform to an existing City of Hope drug candidate (a nucleoside- based therapy) that is currently under investigation by City of Hope at the cancer center’s main campus near Los Angeles, California.
“January Therapeutics is thrilled to work alongside City of Hope to apply our novel albumin nanoparticles to their investigational therapy,” said Sam Ellis, CEO of January Therapeutics. Scientists from January will encapsulate the drug candidate in the company’s albumin nanoformulation. Subsequent studies of this new chemical entity will then be conducted by the research teams at City of Hope.
“City of Hope is excited to evaluate the impact that January’s platform can have on our investigational therapy,” said Steven T. Rosen, M.D., provost and chief scientific officer at City of Hope, noting that the concept of albumin encapsulation has been scientifically validated as a means of targeting cancer cells.
The details of the collaboration were not released, but the company indicated that the collaboration may potentially expand as data from the research becomes available.
January Therapeutics, an emerging oncology research and development company, announces a panel of renown scientific advisors
January Therapeutics, Inc., was formed around a proprietary therapeutic platform dubbed the Chemistry-enabled Albumin Nanoparticle (CAN) Platform. The company recently named a number of experts to provide advice on the development of the various compounds in the January pipeline.
"We have assembled a distinctive group of respected leaders in the fields of cancer research and drug development," said Sam Ellis, January's CEO, "and we look forward to collaborating with them in the development of our promising pipeline of therapeutics."
The scientific advisors include:
Copyright © 2021 January Therapeutics - All Rights Reserved.